Assessing discriminative performance at external validation of clinical prediction models by Nieboer, D. (Daan) et al.
RESEARCH ARTICLE
Assessing Discriminative Performance at
External Validation of Clinical Prediction
Models
Daan Nieboer1*, Tjeerd van der Ploeg2, Ewout W. Steyerberg1
1 Department of Public Health, Erasmus MC—University medical center, Rotterdam, the Netherlands,
2 Department of Science, Medical Center Alkmaar/Inholland University, Alkmaar, the Netherlands
* d.nieboer@erasmusmc.nl
Abstract
Introduction
External validation studies are essential to study the generalizability of prediction models.
Recently a permutation test, focusing on discrimination as quantified by the c-statistic, was
proposed to judge whether a prediction model is transportable to a new setting. We aimed
to evaluate this test and compare it to previously proposed procedures to judge any
changes in c-statistic from development to external validation setting.
Methods
We compared the use of the permutation test to the use of benchmark values of the c-statis-
tic following from a previously proposed framework to judge transportability of a prediction
model. In a simulation study we developed a prediction model with logistic regression on a
development set and validated them in the validation set. We concentrated on two scenar-
ios: 1) the case-mix was more heterogeneous and predictor effects were weaker in the vali-
dation set compared to the development set, and 2) the case-mix was less heterogeneous
in the validation set and predictor effects were identical in the validation and development
set. Furthermore we illustrated the methods in a case study using 15 datasets of patients
suffering from traumatic brain injury.
Results
The permutation test indicated that the validation and development set were homogenous
in scenario 1 (in almost all simulated samples) and heterogeneous in scenario 2 (in 17%-
39% of simulated samples). Previously proposed benchmark values of the c-statistic and
the standard deviation of the linear predictors correctly pointed at the more heterogeneous
case-mix in scenario 1 and the less heterogeneous case-mix in scenario 2.
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Conclusion
The recently proposed permutation test may provide misleading results when externally val-
idating prediction models in the presence of case-mix differences between the development
and validation population. To correctly interpret the c-statistic found at external validation it
is crucial to disentangle case-mix differences from incorrect regression coefficients.
Introduction
Clinical prediction models receive increasing attention for medical practice and research. After
the development of a prediction model, an external validation study is essential to explore
whether predictions done by the model are valid in a new population [1,2]. The discriminative
ability of prediction models is often quantified using a concordance (c) statistic [3]. The c-sta-
tistic measures whether a prediction model can discriminate between patients with and without
the outcome of interest. For logistic regression models the c-statistic is equivalent to the area
under the receiver operating characteristic (ROC) curve (AUC) [4].
External validation studies are considered the stronger tests for a model compared to inter-
nal validation procedures such as cross-validation or bootstrap resampling [5]. The possible
differences between the validation and development setting make an external validation study
a test of ‘transportability’ of a prediction model [6]. If the validation population contains simi-
lar patients as the development population, the external validation study could merely be con-
sidered a test of the ‘reproducibility’ of a prediction model. Reproducibility refers to the ability
of a prediction model to give valid predictions in a population very similar to the development
population, whilst transportability refers to the ability to give valid predictions in populations
that are related to but different from the development population [6]. Typical examples of tests
of transportability are assessment of model performance across different geographical regions
or in different time periods.
We previously proposed a framework to identify if an external validation study investigated
the reproducibility or transportability of a prediction model [7]. This framework consists of
three steps, 1) investigate the relatedness of the development and validation population, 2) vali-
dation of the prediction model in the new population, and 3) interpreting the results found at
step 2 using the results from step 1. To assess the relatedness between the development and val-
idation sample we proposed a membership model, i.e. a model predicting whether a patient is
from the development or validation sample. Moreover, we suggested to compare the standard
deviation of the linear predictors between development and validation samples, where the lin-
ear predictor is the linear combination of the regression coefficients from the model and the
covariate values in the development and validation samples respectively.
Recently a permutation test was introduced with the aim to consolidate step 1 & 2 into a sin-
gle step [8]. The permutation test tests the hypothesis that the development and validation
population are homogeneous. The permutation test obtains a p-value by judging the change in
c-statistics of the model between the development and validation samples. The permutation
test assesses the degree of homology between the development and validation sets. When the
permutation test gives a p-value below a pre-specified threshold, typically 0.05, the hypothesis
that the development and validation samples are homogeneous is rejected. The claim was that
the model may then not be directly transported to the validation population without further
revision or updating [8].
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Previous research has shown that the c-statistic does not only depend upon the validity of
the prediction model, i.e. correctness of the regression coefficients, but also on the case-mix, i.e.
the heterogeneity between patients in the population [9]. A measure of the case-mix heteroge-
neity is the standard deviation of the linear predictor in a sample. Benchmark values of the c-
statistic have also been developed to disentangle case-mix effects from the effects of incorrect
regression coefficients [10]. One such benchmark value is called the model based c-statistic
(mbc). This is the expected c-statistic in a population given that the predictions made by a
model are perfectly valid.
We aimed to evaluate the usefulness of the recently proposed permutation test in relation to
the previously proposed framework. Specifically, we compare the conclusions from this test
with conclusions drawn using earlier proposed measures, i.e. the standard deviation of the lin-
ear predictor and benchmark values of the c-statistic. We evaluated the different measures
using a simulation study and in a case study using 15 datasets containing patients suffering
from traumatic brain injury (TBI).
Methods
We considered three strategies to judge a change in c-statistic when externally validating a pre-
diction model: a permutation test; the standard deviation of the linear predictor; and bench-
mark values of the c-statistic.
Simulation study
To assess the performance of the proposed permutation test we conducted a simulation study.
In the simulation we varied the case-mix differences and predictor effects between the develop-
ment and validation population, we also varied the sample sizes available for development and
validation. In our simulation study we generated a development setD and validation set V
using the following model:
yij  bernoulliðpijÞ;
pij ¼ logit1ðbjxijÞ;
xijeNð0; s2j Þ;
Where i denotes the patient number and j 2 {D, V} indicates whether the patient belongs to
the development or validation set.
We distinguished three scenarios. In the first scenario we assumed that the case-mix distri-
bution and predictor effects in the development and validation dataset are homogeneous. In
the second situation we assumed that the case-mix is more heterogeneous and predictor effects
were weaker in the validation set compared to the development set. In the third situation we
assumed that the case-mix was less heterogeneous in the validation set as compared to the
development set, but that the predictor effects were similar. The different values of the parame-
ters in the different situations are shown in Table 1.
For each situation we generated development and validation sets containing 40, 100 or 200
patients, resulting in 9 scenarios in total. We developed a prediction model in the development
set using logistic regression and validated the resulting model in the validation set. Subse-
quently we calculated the standard deviation of the linear predictor in the development and
validation sets, the ratio of the standard deviation of the linear predictor in the validation and
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development set, two benchmark values for the c-statistic and performed the permutation test.
R-scripts used for the simulation study are available as supplementary material (S1 Appendix).
Case study
Our case study uses data from the IMPACT database [11]. This database contains data from 15
studies with patients suffering from traumatic brain injury (TBI). This database was previously
used to develop a prediction model predicting 6-month mortality and unfavorable outcome
using patient characteristics such as age, motor score and pupillary reactivity [12]. In our case
study we developed a model predicting 6 month mortality using the on the international arm
of the Tirilizad trial [13]. The prediction model contained the predictors age, motor score and
pupillary reactivity. We subsequently validated the developed model in the remaining 14 stud-
ies and judged the change in c-statistic observed at development and at external validation
using the ratio of the standard deviation of the linear predictor in the validation and develop-
ment set, benchmark values of the c-statistic, and the permutation test. All statistical analyses
were done in R 3.1.2 [14].
Permutation test
The permutation test was developed to test the null hypothesis that the development and vali-
dation populations are homogeneous. When the null-hypothesis is not rejected it should be
safe to transport the prediction model from the development to the validation population. We
then claim that the model is valid in the validation population The permutation test starts with
calculating the observed c-statistic at external validation, denoted by cV, of a prediction model.
The c-statistic is calculated by comparing predictions from the model to observed outcomes.
Subsequently patients are randomly permuted between the development and validation popu-
lation. A prediction model is developed on the permuted development set and the c-statistic of
this model is estimated in the permuted validation population. This process is repeated k times.
The p-value of the permutation test is given by the proportion of times that the c-statistic of the
model developed on the permuted development set was smaller than cV. Whenever the p-value
is below a prespecified threshold, typically 0.05, the null hypothesis is rejected that the develop-
ment and validation population are homogeneous. The prediction model should then be
updated before being transported to the validation population. For our simulation and case
study we used a value of k equal to 1,000.
Measures of case-mix
A direct way to investigate the difference in case-mix between the development and validation
population is to compare the standard deviation (SD) of the linear predictor of the prediction
Table 1. Parameters of the different scenarios in the simulation study.
SD predictor development
population (σD)
SD predictor validation
population (σV)
Coefﬁcient development
population (βD)
Coefﬁcient validation
population (βV)
Homogeneous populations 1 1 3 3
Different case-mix & predictor
effects
1 1.5 3 2
Different case-mix & same
predictor effects
1 0.75 3 3
SD: standard deviation
doi:10.1371/journal.pone.0148820.t001
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model in the development and validation population. The linear predictor is the linear combi-
nation of the regression coefficients from the model and the covariate values in the develop-
ment and validation samples respectively:
lpD ¼ XDbD; lpV ¼ XVbD:
A population with a more heterogeneous case-mix has a higher SD of the linear predictor
compared to a more homogeneous case-mix.
Benchmark values
The discriminative ability of a prediction model at external validation can be influenced by
both the correctness of regression coefficients and the case mix heterogeneity in the validation
sample. This was a key point in our proposed framework and other work [7,10]. Since differ-
ences in case-mix have no impact on the validity of the prediction model it is important to dis-
tinguish between the influence of incorrect regression coefficients and case-mix. Therefore,
two benchmark values of the c-statistic were proposed, the model based c-statistic (mbc) and
the c-statistic obtained by refitting the model in the validation sample (crefitted) [10]. The mbc is
the expected c-statistic in a population given that the prediction model is correct. Differences
between the mbc and observed c-statistic at external validation (cV) indicate the extent of poor
model fit independent of differences in case-mix between development and validation samples.
The mbc can be obtained by first calculating the predicted probability for each patient in the
validation sample and subsequently generating a new outcome value based on this probability
[10]. To ensure stable estimates of the benchmark values at least 100 repetitions for each sub-
ject are required. The refitted c-statistic (crefitted) gives an upper bound on the performance of
the model in the validation population, if the regression coefficients from the prediction model
are perfectly valid. Comparison of cV and crefitted reflects the influence of incorrect regression
coefficients, given a similar case-mix as in the validation population. The mbc uses the regres-
sion coefficients from the prediction model developed in the validation sample, while crefitted
uses regression coefficients from the validation sample. Interpretation of cV is possible by con-
sidering the combination of the validity of the regression coefficients (as learned from compari-
son to crefitted) and the case-mix (difference to development sample learned from comparison
to mbc).
Results
Simulation study
In the scenario where the development and validation population were homogeneous, and the
development and validation sets were relatively small, the median cD and cV were both 0.92
(Table 2). Benchmark values of the c-statistic indicated that the regression coefficients of the
model and case-mix between the development and validation sets were similar. Since the c-sta-
tistic is a rank based measure, by definition cV and crefitted were equal to each other in our simu-
lations. The standard deviation of the linear predictor was similar in the development and
validation sets, correctly indicating that the case-mix was similar in both samples, the median
ratio of both standard deviations was close to 1. The permutation test rejected the null hypoth-
esis of homogeneity between the validation and development sets in approximately 5% of the
generated samples in the simulation study. Changing the sample size of the development and
validation sets yielded similar results, however the interquartile range became somewhat
smaller.
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When both the case-mix and regression coefficients in the development and validation pop-
ulation were different the median cD and cV were both equal to 0.92. The median mbc was
equal to 0.96, by definition crefitted was equal to 0.92. This indicated that although cV did not
change, a substantially higher c-statistic was expected if the regression coefficients of the origi-
nal model had been correct. With small sample sizes, the median standard deviation of the lin-
ear predictor was 3.23 in the development set and somewhat larger (4.85) in the validation set,
indicating a more heterogeneous case-mix. The median ratio of the standard deviation of the
linear predictor in the validation and development sample also indicated that the case mix was
more heterogeneous in the validation population (1.50). The permutation test rejected the null
Table 2. Results from the simulation study, median and inter-quartile range of 1000 simulations is shown for c-statistics and standard deviations.
Proportion of samples where the permutation test rejected the null hypothesis is shown.
cD cV SD lpD SD lpV Ratio SD lpV
and SD lpD
mbc creﬁtted Proportion samples null-
hypothesis rejected
Same case-mix and
predictor effects
Small sample (epv: 20) 0.92
(0.89–
0.95)
0.92
(0.90–
0.95)
3.14
(2.52–
4.30)
3.16
(2.57–
4.14)
1.01 (0.91–
1.12)
0.93
(0.90–
0.95)
0.92
(0.90–
0.95)
0.06
Medium sample size
(epv: 50)
0.92
(0.90–
0.94)
0.92
(0.90–
0.94)
3.08
(2.63–
3.52)
3.05
(2.65–
3.55)
1.00 (0.93–
1.07)
0.92
(0.90–
0.94)
0.92
(0.90–
0.94)
0.05
Large sample size
(epv: 100)
0.92
(0.91–
0.93)
0.92
(0.91–
0.93)
3.04
(2.75–
3.37)
3.04
(2.74–
3.39)
0.99 (0.95–
1.05)
0.92
(0.91–
0.93)
0.92
(0.91–
0.93)
0.06
Different case-mix and
predictor effects
Small sample (epv: 20) 0.92
(0.89–
0.95)
0.92
(0.89–
0.95)
3.23
(2.58–
4.14)
4.85
(3.89–
6.22)
1.49 (1.35–
1.67)
0.96
(0.95–
0.98)
0.92
(0.90–
0.95)
0.03
Medium sample size
(epv: 50)
0.92
(0.90–
0.94)
0.92
(0.90–
0.94)
2.06
(2.67–
3.67)
4.56
(4.00–
5.32)
1.50 (1.41–
1.60)
0.96
(0.95–
0.97)
0.92
(0.90–
0.94)
0.01
Large sample size
(epv: 100)
0.92
(0.91–
0.93)
0.92
(0.91–
0.94)
3.04
(2.75–
3.37)
4.56
(4.12–
5.06)
1.50 (1.43–
1.57)
0.96
(0.95–
0.97)
0.92
(0.91–
0.94)
0.02
Different case-mix and
same predictor effexts
Small sample (epv: 20) 0.92
(0.89–
0.95)
0.88
(0.85–
0.92)
3.22
(2.55–
4.23)
2.42
(1.90–
3.18)
0.75 (0.67–
0.84)
0.89
(0.86–
0.93)
0.88
(0.85–
0.92)
0.18
Medium sample size
(epv: 50)
0.92
(0.90–
0.94)
0.88
(0.86–
0.90)
3.08
(2.63–
3.61)
2.30
(2.01–
2.70)
0.75 (0.70–
0.80)
0.89
(0.86–
0.91)
0.88
(0.86–
0.90)
0.25
Large sample size
(epv: 100)
0.92
(0.91–
0.93)
0.88
(0.86–
0.90)
3.03
(2.74–
3.37)
2.27
(2.06–
2.52)
0.75 (0.71–
0.79)
0.88
(0.87–
0.90)
0.88
(0.86–
0.90)
0.39
cD: c-statistic of the model in the development population
cV: c-statistic at external validation
SD lpD: standard deviation linear predictor in development population
SD lpV: standard deviation linear predictor in validation population
mbc: model based c-statistic
creﬁtted: c-statistic of model reﬁtted in the validation population
doi:10.1371/journal.pone.0148820.t002
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hypothesis in 3% of the generated samples. Results using larger sample sizes were similar, how-
ever the interquartile range became somewhat smaller.
In the third scenario, the case-mix in the validation population was less heterogeneous com-
pared to the development population. Using small sample sizes for model development and
validation, the median cD was 0.92 and the median cV was 0.88. The median mbc was equal to
0.89 and median crefitted was 0.88, indicating that the drop in c-statistic between the develop-
ment and validation set was due to a less heterogeneous case-mix in the validation set rather
than incorrect regression coefficients. The median standard deviation of the linear predictor in
the development population was 3.22 and somewhat smaller (2.42) in the validation set, indi-
cating that the case-mix distribution was less heterogeneous in the validation set, which was
confirmed by the median ratio of the standard deviations (0.75). The permutation test rejected
the null hypothesis of homogeneous population in approximately 18% of the cases. Increasing
the available sample sizes of the development and validation sets showed similar results, except
for the permutation test where the proportion of samples where the null hypothesis was
rejected increased to 39% as the available sample size increased, reflecting more statistical
power. Again the inter-quartile range became somewhat smaller.
Case study
The prediction model developed in the international arm of the Tirilizad trial had a c-statistic
of 0.71 [0.67–0.74 95%CI]. The standard deviation of the linear predictor at development was
equal to 0.80. When the model was externally validated the c-statistic ranged between 0.64 and
0.85 (Table 3). If the standard deviation of the linear predictor was larger in the validation sam-
ple than in the development sample, then the model based c-statistic (mbc) was larger than the
Table 3. External validation results of the model predicting 6-monthmortality in TBI patients using age, motor score and pupillary reactivity.
Study cV mbc SD lpV Ratio SD lpV and SD lpD creﬁttted p-value permutation test
TINT 0.711 - - - - -
TIUS 0.74 0.73 0.87 1.09 0.74 1.00
SLIN 0.68 0.69 0.71 0.89 0.68 0.00
SAP 0.69 0.74 0.95 1.19 0.74 0.00
PEG 0.76 0.78 1.17 1.46 0.77 1.00
HIT I 0.72 0.77 1.12 1.40 0.79 0.90
UK4 0.81 0.78 1.16 1.45 0.83 1.00
TCDB 0.82 0.80 1.25 1.56 0.83 1.00
SKB 0.68 0.75 1.01 1.26 0.72 0.35
EBIC 0.83 0.79 1.24 1.55 0.85 1.00
HIT II 0.69 0.77 1.10 1.38 0.73 0.00
NABIS 0.69 0.76 1.04 1.30 0.72 0.55
CSTAT 0.75 0.72 0.86 1.08 0.77 1.00
PHARMOS 0.64 0.70 0.76 0.95 0.66 0.00
APOE 0.85 0.73 0.86 1.08 0.85 1.00
1c-statistic of the model at development
cV: c-statistic observed at external validation
mbc: model based c-statistic
SD lpV: standard deviation of the linear predictor in the validation data
SD lpD: standard deviation of the linear predictor in the development data
creﬁtted: c-statistic of the prediction model reﬁtted in the validation data
doi:10.1371/journal.pone.0148820.t003
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c-statistic at development. This reflected the wider spread of the risk distributions. The permu-
tation test indicated evidence of heterogeneity between the development and validation sample
in 4 out of 14 validations. However, the mbc and the standard deviation of the linear predictor
indicate that the decrease in c-statistic in the SLIN study was mainly attributable to a less het-
erogeneous case-mix distribution, rather than incorrect regression coefficients. The permuta-
tion test indicated no evidence of heterogeneity in 10 out of the 14 validation studies.
Evaluation of the mbc and standard deviation of the linear predictor led to the same conclusion
for the TIUS and PEG studies. In the other 8 cases there was a substantial influence of incorrect
regression coefficients on the observed c-statistic at external validation, indicating that the
model was not transportable to these settings.
Discussion
This study illustrated how two separate phenomena determine differences in observed discrim-
inative ability, i.e. the c-statistic, between development and validation settings. Case-mix and
the correctness of regression coefficients both influence the c-statistic of a prediction model
when applied in a new datasets. Attempts to provide a single summary test for differences in c-
statistic are therefore misleading. The recently proposed permutation test incorrectly con-
cluded that the development and validation population were not homogeneous in the scenario
with different case-mix but similar predictor effects. Conversely the permutation test con-
cluded that development and validation population were homogeneous when the case-mix was
more heterogeneous but predictor effects were weaker. Similar patterns were observed in the
case study.
The permutation test aimed to consolidate the first two steps in the framework proposed by
Debray et al. [7], by judging the heterogeneity between development and validation population
using the change in c-statistic of the prediction model. The c-statistic however does not only
depend on whether a prediction model gives valid predictions, but also on the case-mix in the
underlying population; that was the key point in the framework by Debray. The permutation
test does not take these case-mix differences into account and may break down when these are
present.
When validating the IMPACT prediction model, predicting 6-month mortality of patients
suffering from traumatic brain injury, it was noted that the c-statistic at external validation was
higher in datasets from observational studies compared to the c-statistic found when validating
in datasets from randomized controlled trials [15]. These differences were attributed to the
wider enrollment criteria in the observational studies compared to trials, leading to a more het-
erogeneous case-mix in the observational studies compared to the trials. Similarly, a recent
review found higher c-statistic values in some validation studies than in the development stud-
ies, again suggesting that more heterogeneity at validation is well possible [16]. The overall pat-
tern in this review was a lower performance at validation than expected, reflecting
overoptimism and overfitting at model development [4].
At external validation the performance of a prediction model is assessed using data not used
at model development. Here we focused on judging the change in c-statistic of the prediction
model at external validation. Validation studies however should also aim to assess other model
properties, in particular the calibration of a prediction model. Calibration refers to the agree-
ment between predicted probabilities and observed outcomes. It can adequately be assessed
using recalibration parameters, and graphically using calibration plots [4,17].
The standard deviation of the linear predictor is a simple measure of case-mix heterogeneity
in a dataset. When the distribution of the linear predictor is skewed the standard deviation
may not be appropriate as a measure of case-mix heterogeneity. We note however that the
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distribution of the linear predictor is often close to a normal distribution [18]. At external vali-
dation the distribution of the linear predictor should be assessed graphically in a ‘validation’
plot [19,20].In sum, the proposed permutation test does not take case-mix differences into
account and can therefore give misleading results in the presence of case-mix differences. The
permutation test therefore is only useful when there are no case-mix differences between the
development and validation set. Case-mix differences between development and validation set-
ting can readily be detected by simple summary measures such as the variance of the linear pre-
dictor or benchmark values of the c-statistic. To judge the change in c-statistic of a prediction
model at external validation it is crucial to disentangle the effects of incorrect regression coeffi-
cients from differences in case-mix heterogeneity between the development and validation
setting.
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